In the ever-complex world of healthcare, partnership with a venture capital firm can truly make the difference between success and failure. Frazier Healthcare Ventures is a firm that understands the unique challenges and risks facing a growing entrepreneurial company in the healthcare industry because their sole focus is, and always has been, healthcare investing.
Founded in 1991 and with more than $1.2 billion of capital under management, Frazier Healthcare is one of the nation’s leading providers of venture and growth equity capital to emerging healthcare companies. Having invested in more than 90 emerging healthcare companies, Frazier Healthcare is well known for its depth of experience and the technical expertise of its investment team. This experience encompasses product development and launch, clinical trial implementation and design, industry operating experience, academic research and clinical practice.
Partnering with Frazier Healthcare provides access to capital and an unparalleled breadth of relevant healthcare industry experience. They take pride in the fact that they not only provide venture and growth capital but also contribute to successful outcomes by working side by side with their entrepreneurs to help them address the many challenges that they encounter on the road to success.
Deep industry experience and domain expertise have been a hallmark of the Frazier Healthcare investment team since its founding and matches well with the complexity of the healthcare industry. The experience of their investment team covers the entire spectrum of the healthcare industry. The following experience is represented on the investment team:
* Private equity investing – More than 70 years of combined healthcare private equity investment experience.
* Design and implementation of clinical trials – Seven members of their team have been involved in or managed trials for Eli Lilly, GlaxoSmithKline, Genentech, Merck, J&J, Immunex, COR and Millennium.
* Former operating industry executives – Nine members of their team have been employed in the industry with such firms as Eli Lilly, GlaxoSmithKline, Immunex, ICOS, Millennium, COR, Affymax, Quinton Instruments, Medtronic, First Health and Ventritex.
* Product development and launch – Ten members of their team have been involved in developing and launching products, such as Integrilin, Cialis, Velcade and Enbrel, at leading biotech, pharma and medical device companies.
* Regulatory – Five members of their team have direct experience in working with the FDA to achieve approval of clinical development programs in both devices and drugs.
* M.D.s – Five members of their team are M.D.’s. Two in the field of cardiology, two in internal medicine, and one in biochemistry.
* Academia – Four members of their team have been on the faculty of leading medical schools: University of Washington, University of Michigan, Harvard University, Stanford University and Indiana University.
Since the formation of Frazier Healthcare Ventures over fifteen years ago the firm has leveraged its core investment team by engaging a number of experienced senior executives, successful entrepreneurs, and leading scientists as members of its affiliate team. Affiliate team participants perform a variety of full time and part time roles as Senior Advisors, Venture Partners, Executive-In-Residences and/or key members of start-up teams. These experienced individuals provide industrial, technical, clinical, and regulatory input to their sector groups and portfolio companies and often get directly involved with launching new companies. They bring unique perspectives and valuable insights from years of experience in the industry as well as deep industry networks that benefit both the Frazier Healthcare investment team and portfolio companies.
This and additional information about Frazier Healthcare Ventures are available on their website.
